Charles River Posts Loss In Q2; Increases 2026 Guidance For Revenue, Non-GAAP EPS
Charles River Laboratories (CRL) reported Q2 net loss attributable to common shareholders of $1.48M versus $52.33M net income a year earlier. Revenue fell to $1.00B from $1.03B. GAAP EPS guidance for 2026 was lowered to $3.05-$3.35, while non-GAAP EPS guidance was raised to $11.15-$11.45; revenue growth guidance updated to 0.0%-1.0%.
How this was made
The 30-second read
Why it matters
Traders can reprice the forward earnings trajectory based on the raised 2026 non-GAAP EPS range and updated revenue growth outlook, while monitoring whether GAAP earnings remain pressured by divestiture-related items.
Market read
A guidance update with explicit 2026 ranges plus a same-day premarket jump creates a near-term trading catalyst for CRL.
What to watch
Revenue is still slightly down year over year (2.7%), and organic growth is only +0.1%, so the guidance raise may rely on normalization rather than strong current momentum.
Background
Charles River Laboratories reported Q2 results with GAAP net loss and provided updated 2026 guidance for revenue and non-GAAP EPS.
Ticker impact
Charles River reported Q2 GAAP and non-GAAP losses and raised 2026 revenue and non-GAAP EPS guidance, driving a premarket +8.8% move.
Near-term upside bias likely persists while traders focus on the raised 2026 non-GAAP EPS and revenue growth range; GAAP optics may cap rallies.
The article discloses both the Q2 results and the specific 2026 guidance revisions (GAAP EPS lowered, non-GAAP EPS raised), plus an immediate premarket reaction, which together inform a tradable near-term narrative.
Market effects
Biopharma services and CRO sentiment may improve modestly if guidance raises signal demand resilience, though this is company-specific.
Limited, primarily US small-to-mid cap biotech services sentiment.
Low, as the disclosure is company-specific and not a global macro or regulatory event.
Counterpoint
The GAAP EPS guidance was cut sharply due to divestiture-related net loss, so the raised non-GAAP numbers may not translate into GAAP earnings power.
Key entities
- companyCharles River Laboratories International
Reported Q2 net loss and updated 2026 revenue and non-GAAP EPS guidance; shares up 8.8% premarket.
